Status:

TERMINATED

Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments

Lead Sponsor:

Positive Trial Group

Conditions:

Hypercholesterolemia

Type 2 Diabetes

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

The study is being conducted to compare the effect of standard treatment (target LDL-C level: \<120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: \<70 mg/dL) in the pre...

Eligibility Criteria

Inclusion

  • Patients meeting the following inclusion criteria will be included in the study:
  • Patients giving voluntary written consent to participate in the study
  • Male or female patients 50 years of age or older (at informed consent)
  • Hypercholesterolemia patients (Untreated patients: LDL-C level ≥140 mg/dL; treated patients: LDL-C level ≥120 mg/dL)
  • Type 2 diabetes patients (HbA1c level ≥6.1% (JDS criteria), with or without history of drug therapy)
  • Hypertension patients (SBP ≥130 mmHg or DBP ≥80 mmHg, with or without history of drug therapy)
  • Patients with two or more of the following risk factors
  • Male
  • 65 years of age or older
  • Smoker
  • L/H ratio: ≥3.0 •HbA1c level: ≥8.0%
  • Left ventricular hypertrophy
  • First- or second-degree family history of MACE
  • Microalbuminuria (quantitative testing: ≥30 mg/dL), proteinuria (qualitative testing: + or higher) or eGFR (\<60 mL/min/1.73 m2)

Exclusion

  • Patients meeting the following criteria will be excluded from the study:
  • Patients receiving rosuvastatin, pitavastatin, or atorvastatin therapy within one month prior to informed consent
  • Patients judged to have familial hypercholesterolemia
  • Patients with a serum triglyceride level of ≥400 mg/dL
  • Patients with a history of myocardial infarction
  • Patients with a history of coronary revascularization (PCI or CABG)
  • Patients with a history of treatment of unstable angina
  • Patients with a history of cerebrovascular accident (excluding asymptomatic lacunar infarction)
  • Heart failure patients
  • Patients with a history of hypersensitivity to statins
  • Patients with a history of drug-induced myopathy
  • Patients with poorly controlled arrhythmia
  • Patients with severe liver or kidney disease
  • Patients with serious concurrent disease, such as malignancy, or patients with severely limited lifespan
  • Patients who are or may be pregnant
  • Patients judged by the investigators to be ineligible for participation in the study for any other reason

Key Trial Info

Start Date :

July 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

10000 Patients enrolled

Trial Details

Trial ID

NCT01173939

Start Date

July 1 2010

Last Update

June 1 2011

Active Locations (317)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 80 (317 locations)

1

Hiramitsu Heart Clinic

Nagoya, Aichi Pref., Japan

2

Medical Dock&Clinic

Nagoya, Aichi Pref., Japan

3

Matsuno Medical Clinic

Iyo Gun, Ehime Pref., Japan

4

Ishite Matsumoto Naika Junkanki Clinic

Matsuyama, Ehime Pref., Japan

Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments | DecenTrialz